We discuss the tolerability of new AEDs in comparison with the established compounds. The drawbacks and limitations of the clinical trials are underlined. It is concluded that some new AEDs (LTG, GBP, OXC) are better tolerated than the older ones while other compounds (GVG, FLB) are perhaps more dangerous than the traditional drugs. The distinction between 'new' and 'old' drugs is meaningless and misleading.
|Translated title of the contribution||The new antiepileptic drugs: Are really better tolerated? The pro|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Clinical Neurology